Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Orthopoxvirus-specific serum antibody response evolution
研究概览
简要总结
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
详细描述
Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge.
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is scheduled to receive a booster dose of MVA-BN
- •Willingness to provide written informed consent
- •Willingness to follow the study schedule
排除标准
- •1. Past or current MPXV infection
结局指标
主要结局
Orthopoxvirus-specific serum antibody response evolution
时间窗: from enrollment to the end of follow up at 2 years
To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination
次要结局
- Orthopoxvirus-specific systemic cellular immune response evolution(from enrollment up to 2 years)
- Orthopoxvirus-specific mucosal antibody & cellular immune response evolution(from enrolment up to two years)